

Index

A

- Abdomen, vascular injuries to, 128–130
- Abdominal aortic aneurysms, 12, 13, 193–207
 - clinical features of, 194
 - complications of, 204
 - definition of, 193
 - diameter of, 196–197
 - endovascular repair of, 202–204, 249–250
 - anesthesia for, 67
 - long-term costs of, 25
 - epidemiology of, 193
 - familial, 192
 - inflammatory, 206–207
 - non-ruptured (elective), management of, 196–204
 - anesthesia for, 66
 - aneurysmal expansion rate in, 197
 - aneurysmal size in, 196–197
 - complications of, 200–202
 - endovascular repair technique, 202–204
 - open repair technique, 199–202
 - patient comorbidity in, 197
 - preoperative assessment in, 198–199
 - proximal extent of aneurysm in, 197
 - surgeon's audited results in, 198
 - pathogenesis of, 192
 - radiological investigations of, 29, 35–36
 - risk factors for, 193–194
 - ruptured
 - gender differences in, 193
 - leaking, 205
 - as mortality cause, 193, 204–206
 - operative repair of, 198, 204–206
 - in peripheral arterial disease patients, 53
 - symptoms of, 205
 - screening for, 196
- Accreditation Council for Graduate Medical Education (ACGME), 153
- Acrocyanosis, 79
- Activated clotting time (ACT), 41
- Activated partial thromboplastin time (aPTT), 41, 43
- Activated protein C resistance (APCR), 48
- Acute mesenteric ischemia (AMI), 231–234
- Adrenaline, 172
- β -Adrenergic antagonists, 59
- Advanced Trauma Life Support (ATLS), 129
- Afterload, cardiac, aortic cross-clamping-related increase in, 68
- Agency for Healthcare Research and Quality (AHRQ), 149
- Alternative medical therapy, for lower limb ischemia, 95
- Amaurosis fugax, 161, 163
- Ambulatory venous pressure (AVP), 107
- American Board of Surgery, 153
- Amputations
 - Buerger's disease-related, 87
 - combat injuries-related, 125
 - concomitant vascular and nerve injuries-related, 130
 - in diabetic patients, 58
 - lower limb ischemia-related, 95, 97–98, 100
 - peripheral vascular disease-related, 53
- Analgesia, 241
- “Anatomical snuff box”
 - as arteriovenous fistula access site, 142
 - pulse in, 13
- Anesthesia, for vascular surgery, 65–72, 241
 - for carotid endarterectomy, 69–70, 172, 176
 - for endovascular interventions, 66–67
 - general, 65–66, 67–69, 69, 172, 176
 - local anesthesia, 240
 - in carotid endarterectomy, 172
 - for lower extremity vascular surgery, 70–71



- Anesthesia, for vascular surgery (*cont.*)
for upper extremity vascular surgery, 71–72
locoregional, for carotid endarterectomy, 172
regional, 65–66, 69–70, 71–72
contraindications to, 71
risks associated with, 65–66
tumescant, 67
- Aneurysms, 191–219. *See also* Pseudoaneurysms
aortic. *See* Aortic aneurysms
axillary arterial, 218
axillosubclavian arterial, 218–219
“berry,” 88
carotid arterial, 218–219
false, 158
true, 158, 159
classification of, 191–192
definition of, 191
false, 158, 202
femoral arterial, 213–214
iliac arterial, 214
mesenteric arterial, 34, 35, 216
pathogenesis of, 192
popliteal arterial, 13, 210–213
duplex imaging evaluation of, 22–23
as limb ischemia cause, 101, 104
management of, 211–213
popliteal pulse in, 93
ruptured, 211–212
rupture of, 192, 211–212
subclavian arterial, 185, 186, 218
traumatic, 13
visceral arterial, 214–217
- Angiitis, cutaneous leukocytoclastic, 85
- Angina, mesenteric, 34–35
- Angiogenic therapy, for limb ischemia, 98
- Angiography
of abdominal aortic aneurysms, 195–196
in blunt abdominal trauma patients, 129
carotid, 156, 159, 165, 178–179, 188
of the carotid arch, 25
catheter, 26–28
of abdominal aortic aneurysms, 35–36
complications of, 29
of endoleaks, 36
of peripheral vascular disease, 31
pulmonary, 33
complications related to, 140
computed tomography
of peripheral vascular disease, 31
of the proximal common carotid artery, 187
pulmonary, 25
contrast
of carotid disease, 165
of lower limb ischemia, 95
of cystic adventitial disease, 89
digital subtraction, 26
of carotid artery disease, 156, 159
of the proximal common carotid artery, 187
of the subclavian artery, 186–187
for endoleak detection, 36, 250
magnetic resonance, 30
of carotid disease, 165, 166
of the mesenteric arteries, 35
of the proximal common carotid artery, 187
of pulmonary embolism, 33
of the renal arteries, 35
of the subclavian artery, 186–187
post-angioplasty, 245
of renal artery stenosis, 35, 223–224
of subclavian arterial aneurysms, 217
of thoracoabdominal aortic aneurysms, 209
- Angioplasty
percutaneous transluminal
as fibromuscular dysplasia treatment, 88
mesenteric, 234–235
as renal artery stenosis treatment, 226
as supra-aortic trunk disease treatment, 184–185
as renal artery stenosis treatment, 225–226
of the subclavian artery, 187
techniques in, 244–246
- Angioplasty balloons, 245
- Angiotensin-converting enzyme inhibitors, 88, 222
- Angiotensin II, captopril blockade of, 225
- Angiotensin II receptor antagonists, 78
- Ankle block, 71
- Ankle-brachial index (ABI), 19, 150–151
in chronic venous insufficiency, 109
definition of, 15
in diabetes mellitus, 19
effect of exercise testing on, 20
in lower limb ischemia, 93, 94, 95
in peripheral arterial disease, 53, 58
- Antibiotics, indications for use of, 241
- Anticoagulation therapy, 66, 99–100, 127
- Antihypertensive therapy, guidelines for, 59
- Antineutrophil cytoplasmic antibodies (ANCA), 79, 80, 83
- Antioxidant therapy, 8
- Antiphospholipid antibody syndrome, 50
- Antiplatelet therapy, 1, 54–56, 166–167, 172
- Antiplatelet Trialists Collaboration, 56, 166, 167
- Antithrombin III deficiency, 48
- Aorta
abdominal
aneurysms of. *See* Abdominal aortic aneurysms
diameter of, 193
palpation of, 14
thoracic, trauma-related disruption of, 128
traumatic injuries to, 37, 128
- Aortic aneurysms
abdominal. *See* Abdominal aortic aneurysms
thoracoabdominal, 207–210
- Aortic dissection, 36–37, 100
- Aortic reconstruction, complications of, 137



INDEX

- Aortic surgery, open
 anesthesia for, 67–69
 pharmacological considerations for, 68–69
- Aortitis, 81, 208
- Aortobifemoral bypass, long-term results of, 96
- Aortofemoral bypass, 68, 101–102, 102
- Apolipoproteins, 4–5
- L-Arginine, as lower limb ischemia treatment, 95
- Arterial bypass. *See also* specific types of arterial bypass
 as limb ischemia treatment, 101–102
- Arterial pressure index (API), Doppler, 126
- Arterial reconstruction, complications of, 134–135
- Arteriography. *See also* Angiography
 of abdominal aortic aneurysms, 195–196
 arch, of innominate artery occlusive disease, 183
 of axillary artery aneurysms, 218
 of popliteal arterial aneurysms, 211
- Arteriovenous access grafts
 autogenous. *See* fistulas, arteriovenous
 nonautogenous, 141, 143
 complications of, 145–146
- Arteriovenous malformations, pulmonary, 33–34
- Arteritis
 giant cell, 80, 160, 163, 181
 radiation, 160, 185
 Takayasu's, 32, 80–81, 157, 159, 163, 181, 185
- Artery of Adamkiewicz, ligation of, as paraplegia cause, 202
- Aspirin, as hemorrhage risk factor, 39, 40
- Aspirin therapy, 54–55, 76, 166, 167, 241
- Asymptomatic Carotid Atherosclerosis Study (ACAS), 169, 170–171, 173, 179
- Asymptomatic Carotid Surgery Trial (ACST), 169, 170–171, 173
- Atherectomy, 247–248
- Atheroma, 5–6
- Atherosclerosis, 1–8
 of the carotid artery, 156–157
 clinical history of, 10
 epidemiology of, 1–2
 of the innominate artery, 181
 lipid metabolism in, 3–5
 lipid profiles in, 59
 as lower limb ischemia cause, 91, 92, 93
 pathogenesis of, 5–7
 prevention of, 7–8
 radiation-induced, 181
 regression of, 6–7
 risk factors for, 2–5
 of the subclavian artery, 185
 as systemic vascular disorder, 53
 theories of, 5–7
 as thoracoabdominal aortic aneurysm cause, 208
- Atherosclerotic plaques, 5–7
 carotid, 157–158
 fibrous, 5
 fibrous cap of, 5, 157
 rupture of, 7, 157–158
 stable *versus* unstable, 7
- Atrial fibrillation, 156, 167–168
- Atriofemoral bypass grafting, 68
- Atrophie blanche*, 105, 108
- Atropine, 241
- Auscultation, 14
- Axillary artery
 cystic adventitial disease of, 89
 traumatic injuries to, 130
 as vascular access site, 243
 complications of, 140
- Axillary artery/vein dissection, anesthesia for, 71
- Axillobifemoral bypass, in abdominal trauma patients, 130
- Axillofemoral bypass, 66, 68, 71, 102
- Axillosubclavian artery aneurysm, 217
- Azathioprine, as giant cell arteritis treatment, 160
- B**
- Bandaging, multilayer lymphedema (MLLB), 120, 121
- Banding, of arteriovenous fistulas, 145
- Benzodiazepines, 241
- Benzopyrenes, as lymphedema treatment, 122
- Beta blockers, use in peripheral arterial disease patients, 59
- Bleeding disorders, 39–42. *See also* Coagulation disorders
- Blood flow
 mesenteric, 231
 normal venous, 106–107
- Blue digit syndrome, 31
- Blunt trauma, 125
 abdominal, 128–129
 to the carotid artery, 127
 to the extremities, 130, 131
 to the neck, 127, 160
- Bovine branch anomaly, 182
- Brachial artery
 distal, cystic adventitial disease of, 89
 as vascular access site, 243
- Brachial plexus, traumatic injuries to, 126, 130
 clinical assessment of, 128
- Brachial plexus blocks, 71–72
- Breast cancer, mortality rate in, 54
- Breast cancer treatment, as lymphedema-related pain cause, 120
- British Hypertension Society, 59
- Bruits
 carotid, 14, 93, 164–165, 183
 subclavian, 183
 vascular injury-related, 126
- Buerger, Leo, 86
- Buerger's disease, 31, 86–87, 91
- Buerger's test, 14
- Bullets, velocity of, 126
- Bupivacaine, 66, 240

**C**

- Calcitonin gene-related peptide, 74, 78–79
- Calcium channel blockers, as Raynaud's phenomenon treatment, 76, 77–78
- Calf muscle, venous blood pumping function of, 106–107
- Capillaroscopy, 76
- Capillary refill test, 13
- CAPRIE (Clopidogrel *versus* Aspirin in Patients at Risk of Ischemic Events) study, 56, 167
- Captopril, 225
- Carbon dioxide, as vascular contrast media, 27–28
- Cardiac failure, high-output, 145
- Cardiovascular disease, as mortality cause, 1
- Carotid arteries
 - aneurysms of, 218–219
 - false, 158
 - true, 158, 159
 - dissection of, 127, 129, 158–159, 163
 - external, in carotid endarterectomy, 171
 - internal
 - in carotid endarterectomy, 171, 172–173
 - elongation and kinking of, 158
 - fibromuscular dysplasia of, 158
 - occlusive disease of, vertebral artery occlusive disease-associated, 189
 - thrombosis of, as stroke cause, 156
 - proximal common, occlusive disease of, 187–188
 - stenosis of, 22, 182
 - tortuous, 33, 158
 - traumatic injuries to, 127, 160
- Carotid artery disease, 155–180
 - clinical presentation of, 161–163
 - epidemiology of, 155
 - investigation of, 164–166
 - management of, 166–175
 - medical, 166–168
 - surgical, 169–175
 - pathology of, 157–160
 - postoperative management of, 175–179
 - prognosis of, 164
 - radiological investigations of, 32, 33
- Carotid body tumors (CBTs), 32, 160
- Carotid bypass, 175
- Carotid-subclavian bypass, 187
- Carotid surgery, anesthesia in, 69–70
- Catheterization
 - central venous, 141, 142
 - epidural, 66
 - equipment for, 237–240
 - as vascular injury cause, 126
- Catheters, 238–240
 - central venous, 141, 142, 143–144, 146–147
 - complications related to, 140, 146–147
 - for embolotherapy, 251
 - flushing of, 101, 147, 239, 240–241
 - placement of, 244
 - types of, 239–240
- CAVATAS study, 180
- Cavography, 109
- Celiac artery
 - aneurysms of, 216
 - duplex ultrasound examination of, 234
- Cerebral perfusion pressure (CPP), 69
- Cervical plexus block, 69, 70
- Cervical rib, 76, 185, 187, 217
- Charles operation, for lymphedema, 122
- Chest, vascular injuries to, 128
- Chewing tobacco, as Buerger's disease cause, 86
- Cholesterol, hepatic production of, 3
- Churg, Jakob, 84
- Churg-Strauss syndrome, 84–85
- Chylomicrons, 3, 4
- Cilostazol (Pletal), 61–62, 95
- Claudication
 - as amputation cause, 95
 - chronic limb ischemia-related, 10
 - cystic adventitial disease-related, 88
 - exercise testing evaluation of, 20
 - innominate artery occlusive disease-related, 181
 - intermittent, 60
 - drug therapy for, 61–62
 - dyslipidemia-related, 58
 - effect of smoking cessation on, 2
 - exercise programs for, 60
 - lower limb ischemia-related, 53, 91, 92–93, 95, 98
 - medical management of, 54
 - natural history of, 53
 - risk factors for, 55, 58
 - of the jaw, 163
 - neurogenic, differentiated from vascular claudication, 92–93
 - thoracic outlet syndrome-related, 186
 - upper-limb, 11
 - venous, 108
- Clinical status, 150–151
- Clopidogrel, 56, 166, 167, 241
- Clopidogrel *versus* Aspirin in Patients at Risk of Ischemic Events (CAPRIE) study, 56
- Closure devices, arterial, 25, 26, 242
- Clotting disorders. *See* Coagulation disorders
- Coagulation cascade, 42
- Coagulation disorders
 - acquired, 46–47
 - complications related to, 139–140
 - inherited, 42–46
- Cogan's syndrome, 81–82
- Coils, embolic, 251
- Colic artery, aneurysms of, 217
- Colonic ischemia, postoperative, 202, 206
- Colonoscopy, 202
- Colorectal cancer, mortality rate in, 54
- Common femoral artery, orthopedic surgery-related injuries to, 126
- Compartment pressures, measurement of, 103



- Compartment syndrome, 102–103, 103, 130
 Compression injuries, abdominal, 128–129
 Compression therapy, 110–111, 121
 Computed tomography (CT), 28–30. *See also*
 Angiography, computed tomography
 of abdominal aortic aneurysms, 36, 195, 199, 205
 of arteriovenous fistulas, 123
 of carotid disease, 165–166
 of inflammatory abdominal aortic aneurysms, 207
 of innominate artery occlusive disease, 183
 of lower limb ischemia, 93, 95
 of lymphedema, 119
 of popliteal arterial aneurysms, 211
 of subclavian arterial aneurysms, 217
 of thoracic trauma, 128
 of thoracoabdominal aortic aneurysms, 208
 Congestive heart failure, incidence of, 2
 Connective tissue disorders, Raynaud's phenomenon-related, 75, 76
 Continuous quality improvement (CQI), 152–153
 Contrast agents, 26, 27–28
 first use of, 25–26
 nephrotoxicity of, 27, 33, 95, 224
 reactions to, 242
 Cooperative Study of Renovascular Hypertension, 221–222
 Corona phlebectatica (ankle/malleolar flare), 105, 108
 Coronary artery disease (CAD)
 carotid disease-related, 65
 cholesterol as risk factor for, 6
 incidence of, 2
 as mortality cause, 1
 peripheral arterial disease-related, 53
 postoperative, 133
 prevention of, with cholesterol-lowering therapy, 7, 8
 supra-aortic trunk disease-associated, 183
 Coronary-subclavian steal syndrome, 186
 Corticosteroids, as giant cell arteritis treatment, 80, 160
 Cost outcomes, in vascular surgery, 152–153
 Cranial nerve palsy, 159, 218–219
 C-reactive protein, in giant cell arteritis, 80
 Critical closing pressure (CCP), in lower limb ischemia, 93
 Cross-clamping, aortic, effect on cardiac afterload, 68
 Crush injuries, 126, 128
 Cryoglobulinemia, essential mixed, 85
 Cryoglobulins, 85–86
 Cyanoacrylate, 252
 Cyanosis, Raynaud's phenomenon-related, 75
 Cyclophosphamide, 84, 160
 Cystic adventitial disease, 88–89
 Cytokines, 6, 157
- D**
 Debridement, 22, 130
 Deceleration injuries, 126, 128–129
 Decongestive lymphedema therapy (DLT), 120
 Deep venous reconstruction, as varicose veins treatment, 112–113
 Deep venous thrombosis
 abdominal aortic aneurysm repair-related, 202
 chronic venous insufficiency-related, 107
 hypercoagulability-related, 61
 as lymphedema cause, 118
 medical management of, 54
 Dense granule deficiency, 46
 Dermatitis, chronic venous insufficiency-related, 105, 108, 110
 Diabetes mellitus
 ankle-brachial index (ABI) in, 19
 as atherosclerosis risk factor, 1, 2
 hypertension management in, 59, 167
 lower limb ischemia associated with, 91, 97
 negative correlation with abdominal aortic aneurysms, 193–194
 peripheral arterial disease associated with, 55, 58, 59
 Dialysis Outcomes and Practice Patterns Study (DOPPS), 142
 Dialysis patients, vascular access in, 141–148
 Diazepam, 66–67
 Digital pressures, measurement of, 20
 Diphenhydramine, 66–67
 Dipyridamole, 56, 166, 241
 Distal revascularization-interval ligation (DRIL), 145
 Dorsalis pedis artery, absence of, 19
 Dressings, for chronic venous insufficiency management, 109–110
 Drug injection, intraarterial, adverse effects of, 16–17, 131
 Drugs. *See also* names of specific drugs
 as bleeding risk factor, 39, 40
 Dysarthria, 163
 Dysfibrinogenemias, 49
 Dyshypoplasminogenemias, 49
 Dyslipidemia, management of, 58–59
 Dysphagia, 163
 Dysplasia, fibromuscular, 87–88
 of the internal carotid artery, 158
 radiological investigations of, 35
 as renal artery stenosis cause, 222, 225
 as stroke cause, 157
 subtypes of, 158
- E**
 Eczema, 105, 108, 120
 Edema
 chronic venous insufficiency-related, 108–109
 pulmonary, “flash,” 224
 Ehlers-Danos syndrome, 158–159



- Elastases, 7
- Elastic bandages, 110–111, 121
- Elderly patients, brachial emboli in, 12
- Electrocardiography, preoperative, 198
- Elephantiasis, as lymphedema cause, 118
- Embolectomy. *See also* Embolotherapy
as lower limb ischemia treatment, 100–101, 103
- Embolic agents, 251–252
- Embolism
cardiac, as ischemic stroke cause, 156
cholesterol, 161, 162
common sources of, 11
distal, of the supra-aortic trunk, 189
endovascular abdominal aortic aneurysm repair-related, 204
as lower limb ischemia cause, 98–99, 100–101, 103, 104
mesenteric, 232, 233
pulmonary, 32–33, 202
as upper limb ischemia cause, 16, 17
as upper limb vascular disease cause, 11
- Embolotherapy, 250–252
- Endarterectomy
carotid, 169–179
anesthesia for, 66, 69–70
atherosclerotic plaque excision in, 157
bifurcation, of the proximal common carotid artery, 188
cerebral protection in, 69
comparison with carotid angioplasty, 179–180
effect on stroke risk, 169–171
monitoring during, 66
neurological deficits associated with, 176–178
operative principles of, 171–175
postoperative management of, 175–179
preoperative hypertension control for, 167
traditional *versus* eversion, 174
in vertebral artery stenosis/occlusion, 189
transaortic renal, 226
transthoracic innominate, 183, 184
- Endoleaks, 36, 204, 250
- Endothelin-1, in Raynaud's phenomenon, 74–75
- Endovascular approaches and techniques, 237–252.
See also Embolotherapy; Stenting; Stent grafting
for abdominal aortic aneurysms, 67, 202–204
conversion to open repair, 204
access techniques, 242–244
anesthesia in, 66–67
for aneurysmal disease, 249–250
for arterial occlusive disease, 244–249
for arterial trauma, 131
for carotid aneurysms, 218, 219
equipment for, 237–240
medications used in, 240–242
radiological investigations with, 25–26
for renal artery stenosis, 226–227
for supra-aortic trunk disease, 184–185
for Takayasu's arteritis, 81
for thoracoabdominal aortic aneurysms, 210
vascular intervention devices for, 242
- Epidural anesthesia, 66, 71
- Errors, medical, 149
- Erythrocytes, in Raynaud's phenomenon, 75
- Erythrocyte sedimentation rate, 80, 83, 198
- Erythromelalgia, 79
- Estrogen, 39, 75
- European Carotid Surgery Trial (ECST), 169–170
- EuroQol, 152
- Exercise
health benefits of, 60
lymphedema-exacerbating effects of, 122
- Exercise testing, 20
in lower limb ischemia patients, 94–95
- Exercise therapy
for lower limb ischemia patients, 95
for peripheral arterial disease patients, 60
- F**
- Factor deficiencies, 42–45
- Factor inhibitors, 46–47
- Fasciotomy, 102–103, 130
- Fatty streaks, 5
- Femoral arteries
aneurysms of, 13, 213–214
superficial
aneurysms of, 13
distal, occlusive disease of, 96
as hemodialysis access conduit, 147
traumatic injuries to, 130–131
as vascular access site, 243
- Femoral artery punctures, complications of, 131, 140
- Femoral-femoral bypass, 96, 101–102
- Femoral-popliteal bypass, 96
- Femoral shaft fractures, 126
- Femoral-tibial bypass grafting, 97
- Fentanyl, 67
- fibrinogen, 41
- fibrinogen abnormalities, 45
- filiariasis, as lymphedema cause, 118
- fistulas
aortocaval, 194
aortoduodenal, 194
arteriovenous, 123, 124, 128, 131, 141, 142–143
complications of, 144–145
carotid-cavernous sinus, 128
- flavonoids, as lymphedema treatment, 122
- fluid management, perioperative, in patients with ruptured aortic aneurysms, 201
- Framingham Study, 6
- Functional status, 151–152
- G**
- Gadolinium chelate, 28
- Gangrene, 17, 91, 92, 93, 94, 96–97, 131



INDEX

- Gastroduodenal artery, aneurysms of, 216–217
- Gingko, 40, 95
- Glomerulonephritis, Wegener's granulomatosis-related, 84
- Glucocorticoids, as Takayasu's arteritis treatment, 81
- Glucose tolerance test, 58
- Glues, embolic, 252
- Glyceryl trinitrate, 241
- Glycopyrronium bromide, 241
- Grafts, peripheral vascular. *See also* Stent grafting complications related to, 134–139
 infrainguinal, duplex imaging of, 22
 lower limb, occlusion of, 100, 136–137
 as lower limb ischemia risk factor, 91
 polytetrafluoroethylene, 96, 97, 102, 135, 136
 prosthetic, complications of, 137–139
 in supra-aortic trunk disease, 183–184
- Granulomatosis, Wegener's, 83–84
- Gray platelet syndrome, 46
- Greater saphenous vein, radiofrequency or laser ablation of, 67
- Greater saphenous vein grafts, 135
- Growth factor therapy, for limb ischemia, 98
- Guidewires, 237–238, 244–245
 introduction through needles, 244
- Gunshot wounds, 126, 129
- H**
- Hand surgery, anesthesia for, 72
- Health Plan Employer Data and Information Set (HEDIS), 151
- Heart Protection Study, 58, 59
- Hemangiomas, 123
- Hematomas
 of neck incisions, 176
 retroperitoneal, 129
 vascular injury-related, 126, 127, 129
- Hemianopia, homonymous, 162, 163
- Hemophilia, 42–43
- Hemorrhage
 abdominal, trauma-related, 129
 chronic venous insufficiency-related, 109
 femoral artery puncture-related, 131
 intracranial, carotid endarterectomy-related, 177–178
 perioperative, in abdominal aortic aneurysm patients, 201
 thrombolytic therapy-related, 248
 vascular injury-related, 126, 127
 venous, trauma-related, 130
- Henoch, Edouard, 85
- Heparin
 in catheter saline flushes, 101, 147, 239, 240–241
 as contraindication to epidural catheter use, 66
 as hypercoagulability treatment, 47, 48
 intraoperative administration of, 173, 240–241
 as thrombocytopenia cause, 50–51
- Hepatic artery, aneurysms of, 215–216
- Hepatitis C virus, 85, 86
- Herbal remedies, as hemorrhage risk factor, 39, 40, 41
- Hexopal (inositol nicotinate), 61–62
- High-density lipoprotein, 2, 4, 168
- Hollenhorst plaques, 161
- Homan operation, for lymphedema, 122
- Homocysteine, 3, 48–59
- Homocystinemia, 61
- Horner syndrome, 163
 partial, 159
- Human immunodeficiency virus (HIV) infection, 118
- Hunter, William, 125
- Hydrothorax, 37
- 3-Hydroxy-3-methylglutaryl coenzyme (HMG CoA) reductase, inhibition of, 3, 5. *See also* Statin therapy
- 5-Hydroxytryptamine. *See* Serotonin
- Hypercholesterolemia, 1, 6, 193
- Hypercoagulable disorders
 acquired, 47, 50–51, 60–61
 inherited, 47, 48–50, 60, 61
 as ischemic stroke cause, 157
 peripheral arterial disease-associated, 60–61
 supra-aortic trunk disease-associated, 183–184
 as vascular thrombosis cause, 139–140
- Hyperhomocystinemia, 47, 48–49
- Hyperhomocystinuria, 48–49
- Hyperlipidemia, 2, 168
- Hyperperfusion syndrome, as stroke cause, 178
- Hyperplasia, myointimal, 135
- Hypertension
 as abdominal aortic aneurysm risk factor, 193
 as atherosclerosis risk factor, 1, 3
 diabetes mellitus-related, 2
 management of, 59, 167
 drug therapy guidelines for, 59
 fibromuscular dysplasia-related, 88
 incidence of, 2
 as peripheral arterial disease risk factor, 59–60
 postoperative, endarterectomy-related, 176
 renovascular, 221–229
 diagnostic evaluation of, 223–224
 pathophysiology of, 222–223
 renal artery stenosis-related, 225–226
 treatment of, 225–228
 as stroke risk factor, 3, 167
- Hypotension
 endarterectomy-related, 176
 vascular injury-related, 126, 128
- I**
- Ileal artery, aneurysms of, 217
- Ileus, laparotomy-related, 201–202



- Iliac arteries
aneurysms of, 214
cystic adventitial disease of, 89
external, orthopedic surgery-related injuries to, 126
- Iloprost, 76, 78
- Imaging. *See* Radiological investigations
- Impotence, abdominal aortic aneurysm repair-related, 202
- Infections
arteriovenous access graft-related, 146
arteriovenous fistula-related, 145
central venous catheter-related, 144, 146–147
prosthetic graft-related, 137–139
- Inferior mesenteric artery, in abdominal aortic aneurysm repair, 199–200, 202
- Inferior vena cava
as hemodialysis access conduit, 147
traumatic injuries to, 130
- Inflammation
as aneurysmal disease cause, 192, 206
as atherosclerosis cause, 6
- Infrainguinal bypass, as acute ischemia treatment, 102
- Innominate artery
occlusive disease of, 181–185
traumatic injuries to, 128
- Inositol nicotinate (Hexopal), 61–62
- Institute of Medicine, “To Err is Human” report, 149
- Intercostal arteries, in thoracoabdominal aortic aneurysm repair, 209
- Intermediate-density lipoprotein, 3, 4–5
- Internal jugular veins, traumatic injury to, 127
- Internal mammary artery revascularization, as coronary-subclavian steal syndrome cause, 186
- International normalized ratio (INR), 41
- International Society for Cardiovascular Surgery, 151
- Interscalene technique, of deep cervical plexus block, 70
- Intravenous immunoglobulin, as Kawasaki’s disease treatment, 82
- Ischemia
colonic, postoperative, 202, 206
limb. *See* Limb ischemia
mesenteric, 16, 231–234
popliteal arterial aneurysm-related, 211–212
Raynaud’s phenomenon-related, 76
visceral. *See* Visceral ischemic syndromes
- Itching, chronic venous insufficiency-related, 108
- J**
- Jejunal artery, aneurysms of, 217
- K**
- Kaposi’s sarcoma, 118
- Kawasaki, Tomisahu, 82
- Kawasaki’s disease, 82
- Ketanserin, 78
- Klippel-Trenaunay-Weber syndrome, 117
- Knee injuries, 126, 131
- Kocher maneuver, 130
- Korean War, vascular surgery during, 125
- L**
- Lacunar infarcts, 156, 164
- Language disorders, carotid disease-related, 163
- Laparotomy, as ileus cause, 201–202
- Laser ablation, of the greater saphenous vein, 67
- Leap Frog Group, 149–150
- Lecithin-cholesterol acetyltransferase, 4
- Letessier-Meige syndrome, 117
- Lidocaine, 66, 67, 240
- Lifestyle risk factors, clinical evaluation of, 10
- Limb ischemia
lower. *See* Lower limb ischemia
upper limb
clinical examination of, 16–17
radiological investigations of, 32
vascular injury-related, 126
- Limb pressures, segmental, 19–20, 21
- Limb reduction procedures, as lymphedema treatment, 122
- Limbs, vascular injuries to, 130–131
- Limb salvage, in acute lower limb ischemia, 103
- Lipedema, 119
- Lipid-lowering therapy, 7, 8, 58–59
- Lipid metabolism, 3–5
- Lipid profile, “diabetic,” 58
- Lipodermatosclerosis, 105, 108
- Lipoprotein (a), 2, 4
- Lipoprotein lipase, 4
- Liver, cholesterol production in, 3
- Local anesthesia, 240
in carotid endarterectomy, 172
in lower extremity vascular surgery, 70–71
in upper extremity vascular surgery, 71–72
- Long saphenous vein, 106
- Long saphenous vein surgery, for varicose veins, 111–112
- Lorazepam, 67
- Low-density lipoprotein, 1, 2, 3, 4–5, 168
small-density, 2, 4
- Lower limb(s), pallor of, 14
- Lower limb ischemia, 91–104
acute, 98–104
clinical examination of, 16
diagnostic studies of, 99
five P’s of, 99
outcomes of, 103–104
patient history of, 98–99



- physical examination of, 99
 - treatment of, 99–103
 - chronic, 10, 92–98
 - abdominal aortic aneurysm-related, 194
 - clinical examination of, 16
 - diagnostic studies of, 94–95
 - outcomes of, 98
 - patient history of, 92–93
 - physical examination of, 93–94
 - treatment of, 95–98
 - critical, 97
 - acute, 10, 54
 - amputations in, 97–98
 - hypertension treatment in, 59, 60
 - in peripheral vascular disease patients, 53
 - thrombolytic therapy for, 248
 - etiology and presentation of, 91–92
 - postoperative, in abdominal aortic aneurysm patients, 201
 - subclavian artery aneurysm-related, 217
 - treatment of
 - amputation, 97–98
 - medical, 95
 - revascularization, 95–97
 - Lung cancer, mortality rate in, 54
 - Lupus anticoagulant, 50
 - Lymph, formation of, 121–122
 - Lymphadenitis, 118
 - Lymphangiography, 119
 - Lymphangioma circumscriptum, 116
 - Lymphangioma diffusum, 116
 - Lymphangiomas, 116
 - Lymphangiosarcoma, 116, 119
 - Lymphangitis, 118
 - Lymphatic drainage, manual lymphatic (MLD), 120, 121
 - Lymphatic system, anatomy and functions of, 113–114
 - Lymphedema, 113–122
 - acute inflammatory episodes (AIEs) associated with, 118, 121
 - clinical assessment of, 115–116
 - definition of, 114
 - differential diagnosis of, 115
 - epidemiology of, 115
 - etiological classification of, 109
 - factitious, 119
 - familial, 117
 - lymphatic system in, 114
 - management of, 120–122
 - pathophysiology of, 114
 - primary, 114, 116–118
 - relationship with chronic venous insufficiency, 118–119
 - secondary, 114, 118–119
 - Lymphedema congenita, 117
 - Lymphedema praecox, 117
 - Lymphorrhea, 120–121
- M**
- Macrophages, 6, 157, 192
 - Magnetic resonance imaging (MRI). *See also*
 - Angiography, magnetic resonance
 - of abdominal aortic aneurysms, 195
 - of carotid disease, 165–166
 - of popliteal arterial aneurysms, 211
 - of thoracoabdominal aortic aneurysms, 208–209
 - Mannitol, 69
 - Marfan syndrome, 46, 158–159
 - Matrix metalloproteinases, 157, 158, 192
 - Mean arterial pressure (MAP), during carotid endarterectomy, 69
 - Medical Outcomes Short Form 36 (SF-36), 151–152
 - Mesenteric arteries
 - aneurysms of, 34, 35, 216
 - radiological investigations of, 34–35
 - superior
 - aneurysms of, 216
 - duplex ultrasound examination of, 234
 - embolization of, as ischemia cause, 231
 - thrombosis of, as ischemia cause, 231, 233
 - traumatic injuries to, 129–130
 - thrombosis of, 231, 232, 233–234
 - Mesenteric ischemia, acute, 231–234
 - Mesenteric venous thrombosis, 235–236
 - Midazolam, 241
 - Middle cerebral artery, 156
 - Milroy's disease, 117
 - Morphine, 241
 - Motor deficits, carotid disease-related, 162–163
 - Multiple Risk Factor Intervention Trial (MRfIT), 2
 - Mupirocin, 146
 - Muscle death, acute limb ischemia-related, 99, 100
 - Myocardial infarction, 7, 53, 201
 - Myxedema, pretibial, 119
- N**
- Naftidrofuryl (Praxilene), 61–62
 - National Committee for Quality assurance (NCQA), 151
 - National Veterans Administration Surgical Quality Improvement Program (NSQIP), 149
 - Neck
 - anatomic zones of, 127
 - innervation of, 69–70
 - traumatic injuries to, 126, 127–128, 160
 - Neck incisions, hematoma of, 176
 - Nephropathy
 - contrast agent-induced, 27, 33, 95, 224
 - diabetic, lower limb ischemia associated with, 91
 - ischemic, 221, 223, 228
 - Nerve injuries, vascular injuries-associated, 126, 130
 - Neurological deficits, post-carotid endarterectomy, 176–178
 - Neurological examination, of vascular injury patients, 126



- Neuropathy
 diabetic, 71
 ischemic, 104
- Neutrophils, in Raynaud's phenomenon
 pathophysiology, 75
- Nicotine replacement therapy (NRT), 57
- Nifedipine, 76, 241
- Nitroglycerin, 68–69, 78, 241
- Nitroprusside, 68, 69
- Nonsteroidal anti-inflammatory drugs, as
 hemorrhage risk factor, 39, 40
- Noone-Milroy syndrome, 117
- North American Symptomatic Carotid
 Endarterectomy Trial (NASCET), 166,
 169–170, 174
- O**
- Obesity
 adverse health effects of, 57–58
 management of, 57
 in peripheral arterial disease patients, 58
- Ocular disorders, carotid disease-related, 161–162
- Ocular-ischemia syndrome, 161, 162
- Opiates, 241
- Optic nerve, ischemia of, 161, 162
- Orthopedic injuries, treatment for, 130
- Orthopedic procedures, as vascular injury cause, 126
- Osler-Weber-Rendu disease, 46
- Ostial lesions, stenting of, 246
- Outcome measures, in vascular surgery, 149–154
- Ovarian vein reflux, imaging of, 109
- Oxfordshire Community Stroke Project, 164
- Oxyptentifylline (Trental), 61–62
- P**
- Padma Basic, 95
- Pallor, 14, 16, 75, 99
- Palpation, 13–14, 194, 207, 211
- Pancreatic artery, aneurysms of, 216–217
- Pancreaticoduodenal artery, aneurysms of, 216–217
- Papaverine, 241
- Paralysis, acute limb ischemia-related, 99
- Paraplegia, 128, 202
- Paresthesia, acute limb ischemia-related, 99
- Patching, in carotid endarterectomy, 174–175
- Patient satisfaction, 151
- Penetrating trauma, 125
 abdominal, 128
 to the extremities, 130
 to the neck, 127
 thoracic, 128
 weapon-related, 125
- Pentoxifylline, 95
- Perforator ligation, as venous disease treatment, 112
- Peripheral vascular disease
 asymptomatic, in diabetic patients, 58
 atherosclerosis risk factor treatment in, 1
 cholesterol-lowering therapy for, 7
 as coronary artery disease risk factor, 65
 diabetes mellitus associated with, 58
 evaluation instruments for, 152
 as lower limb ischemia cause, 91
 medical management of, 53–63
 vascular risk factor modification, 53–61
 mortality rate in, 53, 54
 radiological investigations of, 31
- Pethidine, 241
- Phleboliths, 123
- Physicians' Health Study, 56
- Platelet-derived growth factor, 54, 135
- Platelet disorders, 45–46
- Platelet factor, 4, 54
- Platelets, in Raynaud's phenomenon
 pathophysiology, 75
- Pletal (cilostazol), 61–62
- Plethysmography, 21, 109
- Pneumothorax, 37
 tension, 128
- Poiseuille's law, 95
- Polyangiitis, microscopic, 85
- Polyarteritis nodosa, 82–83, 85
- Polytetrafluoroethylene grafts, 96, 97, 102, 135, 136
- POPADAD (Prevention of Progression of Arterial
 Disease in Diabetes), 55, 58
- Popliteal artery
 aneurysms of, 13, 210–213
 duplex imaging evaluation of, 22–23
 as limb ischemia cause, 101, 103
 management of, 211–213
 popliteal pulse in, 93
 ruptured, 211–212
 cystic adventitial disease of, 89
 occlusive disease of, surgical treatment of, 96
 orthopedic surgery-related injuries to, 126
 traumatic injuries to, 131
 as vascular access site, 243
- Popliteal pulse, in popliteal aneurysm, 93
- Postimplant syndrome, 204
- Postthrombotic syndrome (PTS), 107
- Praxilene (naftidrofuryl), 61–62
- Prazosin, 74
- Prednisolone, as Wegener's granulomatosis
 treatment, 84
- Pregnancy, "white leg" of, 107
- Prevention of Progression of Arterial Disease in
 Diabetes (POPADAD), 55, 58
- Prilocaine hydrochloride, 240
- Primary valvular incompetence (PVI), 107
- Pringle's maneuver, 129
- Prostate cancer, mortality rate in, 54
- Proteases, 7
- Protein C deficiency, 49
- Protein S deficiency, 49
- Prothrombin time (PT), 41
- Pseudoaneurysms
 of arterial puncture sites, 131, 140



INDEX

- arteriovenous access graft-related, 146
 - carotid, 127–128
 - Pulmonary arteries, imaging of, 32–34
 - Pulmonary disease
 - implication for anesthesia, 71
 - postoperative, 133–134
 - Pulseless disease. *See* Arteritis, Takayasu's
 - Pulselessness, acute limb ischemia-related, 99
 - Pulselessness, vascular injury-related, 126
 - Pulses
 - abdominal, 14
 - carotid, 13–14
 - lower limb, 13
 - subclavian, 13
 - ulnar, 13
 - upper limb, 13
 - Pulse volume recordings (PVRs), 20–21
 - Purpura, Henoch-Schönlein, 85
- Q**
- Quality-adjusted life years (QALYs), 153
 - Quality analysis (QA), 153
 - Quality Interagency Coordination Task Force, 149
- R**
- Radial arteries
 - distal, cystic adventitial disease of, 89
 - traumatic injuries to, 130
 - as vascular access site, 143, 243
 - Radiation, as arteritis cause, 160, 185
 - Radiofrequency ablation, of the greater saphenous vein, 67
 - Radiological investigations, 25–38. *See also* specific radiological imaging modalities in complications of, 140
 - controversies in, 25
 - radiation safety during, 30–31
 - of trauma, 37
 - of vascular diseases, 31–37
 - Radionuclide investigations, mesenteric, 34
 - Raynaud, Maurice, 73
 - Raynaud's phenomenon, 73–79
 - primary, 73, 75
 - differentiated from secondary, 75–76
 - secondary, 73, 74, 75–76
 - thoracic outlet syndrome-related, 186
 - treatment for, 76–79
 - Recombinant tissue-type plasminogen activator, 248
 - Renal arteries
 - aneurysms of, 216
 - radiological investigations of, 35
 - resistive index (RI) in, 223
 - stenosis of, 221–229
 - bruits associated with
 - diagnostic evaluation of, 223–224
 - etiology of, 222
 - experimental models of, 222–223
 - medical management of, 225–226
 - natural history of, 225
 - pathophysiology of, 222–223
 - renal-to-aortic ratio (RAR) for, 223
 - surgical management, 223, 224, 225–228, 246
 - traumatic injuries to, 130
 - Renal function, postoperative, in abdominal aortic aneurysm patients, 201, 206
 - Renal insufficiency. *See also* Nephropathy, ischemic
 - contrast agent-related exacerbation of, 95, 224
 - in lower limb ischemia patients, 97
 - renal artery stenosis-related, 224
 - Renal-to-aortic ratio (RAR), 223
 - Renal vein, left, operative exposure of, 227
 - Renal vein renin assays, 224–225
 - Renography, isotope, 225
 - Reperfusion syndrome, as stroke cause, 178
 - Residency training programs, outcomes measures
 - competency requirement in, 153
 - Resistive index (RI), in the renal artery, 223
 - Rest pain, 10, 11, 92, 93, 98
 - Resuscitation, in abdominal vascular injury patients, 129
 - Retinal artery, occlusion of, 161, 162
 - Rheumatoid arthritis, as lymphedema cause, 119
 - Rib fractures, 128
 - Rubor, 14, 15, 75
- S**
- Saline, heparinized, 101, 147, 239, 240–241
 - Saphenofemoral junction, incompetence of, 14–16, 16
 - Saphenopopliteal junction, ligation of, 112
 - Saphenous vein, as carotid endarterectomy patch, 174–175
 - SAPPHIRE study, 180
 - Schönlein, Johann, 85
 - Sclerotherapy, for chronic venous insufficiency, 111
 - Scottish Intercollegiate Guidelines Network (SIGN), 59
 - Sedation, 241
 - Seldinger technique, 26
 - Selective serotonin reuptake inhibitors, as
 - Raynaud's phenomenon treatment, 78
 - Sensory deficits, carotid disease-related, 162–163
 - Serotonin, 54, 75
 - Serotonin antagonists, as Raynaud's phenomenon treatment, 78
 - Short saphenous vein, 106
 - Short saphenous vein surgery, for varicose veins, 112
 - Shunting, in carotid surgery, 69, 173–174
 - Simvastatin, 8, 59
 - Sinus nerve, in carotid endarterectomy, 173
 - Sistrunk operation, for lymphedema, 122
 - Skin perfusion pressure (SPP), 21–22
 - “Slipped heart syndrome,” 12



- Smoking
as abdominal aortic aneurysm cause, 193
as atherosclerosis cause, 1, 2
as Buerger's disease cause, 86, 87
by occlusive vascular disease cause patients, 12
as peripheral arterial disease cause, 1, 57
as stroke cause, 167
by supra-aortic trunk disease patients, 183
- Smoking cessation
cardiovascular health benefits of, 2
effect on stroke risk, 167
in lower limb ischemia patients, 95
methods, 57
in peripheral arterial disease patients, 1, 57
as weight gain cause, 58
- Society for Vascular Surgery, 151
- Speech disorders, carotid disease-related, 163
- Splenic artery, aneurysms of, 215
- Stab wounds, 126
- Starling's forces, 114
- Statin therapy, 7–8, 59
- Steal, vascular, 145, 146
- Stemmer's sign, 115–116
- Stent grafting, 248
of abdominal aortic aneurysms, 202–204, 249–250
migration of stent in, 204
of carotid artery aneurysms, 219
devices for, 249, 250
postimplantation imaging of, 36
types of stents, 246–247
- Stenting
intravascular, 246–247
of renal artery stenosis, 226–227
of supra-aortic trunk disease, 184–185
techniques in, 246
of thoracoabdominal aortic aneurysms, 210
- Sticky platelet syndrome, 49
- Strauss, Lotte, 84
- Streptokinase, 101, 248
- “String of sausages” sign, 233
- Stroke
atrial fibrillation-related, 167–168
in carotid endarterectomy patients, 176–178
in carotid territory. *See* Carotid artery disease completed, 161
definition of, 155
in evolution, 161
hemorrhagic, 156
incidence of, 2
investigation of, 164–166
ischemic, 156–157, 164
as mortality cause, 164
perioperative, in supra-aortic trunk disease patients, 183–184
peripheral arterial disease-related, 53
prevention of
with antiplatelet therapy, 166–167
with carotid endarterectomy, 169–179
with risk factor modification, 167–168
vertebrobasilar symptoms of, 161, 163, 188–189
- Subclavian arteries
aneurysms of, 185, 186, 217
as arteriovenous fistula access site, 142
occlusive disease of, 185–187
cerebrovascular symptoms of, 11
revascularization of, 187
right, stenosis of, 185
traumatic injuries to, 128, 130
- Subclavian steal, 186
- Subclavian vein, compression of, 186
- Subfascial endoscopic perforator surgery (SEPS), duplex ultrasound-guided, 112
- Suction drains, 175
- “Sunset foot,” 14
- Sympathectomy, as Raynaud's phenomenon treatment, 74, 76–79
- T**
- Takayasu, Mikito, 80
- Thiazides, 59
- Thompson operation, for lymphedema, 122
- Thoracic outlet syndrome, 185, 186, 217
- Thoracic spine, traumatic injuries to, 128
- Thoracotomy
emergent, in thoracic vascular injury patients, 128
in thoracoabdominal aortic aneurysm repair, 209, 210
- Thrombectomy, 249
- Thrombin inhibitors, 47
- Thromboangiitis obliterans. *See* Buerger's disease
- Thromboasthenia, Glanzmann's, 45, 75
- Thrombocytopenia, heparin-induced, 50–51
- Thromboembolism. *See also* Deep venous thrombosis
carotid artery aneurysm-related, 218
as ischemic carotid territory stroke cause, 156
subclavian artery thromboembolism-related, 185
venous, hypercoagulability-related, 48
- Thromboendarterectomy, 227, 235
- β -Thromboglobulin, 54
- Thrombolytic therapy, 101, 248–249
- Thrombophilia
acquired, 60–61
inherited, 60, 61, 105–106
mesenteric venous thrombosis-related, 235
peripheral arterial disease-related, 60–61
- Thrombophilia screen, 41
- Thrombophlebitis, superficial venous, 118
- Thrombosis. *See also* Deep venous thrombosis
as acute lower limb ischemia cause, 98–99, 104
arteriovenous access graft-related, 146
arteriovenous fistula-related, 145
central venous catheter-related, 147
of chronic arterial stenosis, 10
of collateralized chronic stenosis, 16



INDEX

- hypercoagulability-related, 139–140
 - post-endarterectomy, 176–177
 - Thromboxane A₂, 54, 75
 - Tibial nerve, traumatic injuries to, 131
 - Ticlopidine, 166–167
 - Tissue factor, 42
 - Tobacco use. *See also* Smoking
 - as Buerger's disease cause, 86, 87
 - Toe-brachial index (TBI), in lower limb ischemia, 94
 - Topical agents
 - for chronic venous insufficiency-related dermatitis, 110
 - for lymphedema-related eczema, 120
 - Trancutaneous oxygen testing (TcPO₂), 97–98
 - Transient ischemic attacks (TIAs), 161
 - definition of, 155
 - epidemiology of, 155
 - innominate artery occlusive disease-related, 182
 - types of, 161
 - Trauma
 - as acute upper limb vascular disease cause, 11–12
 - as axillary artery aneurysm cause, 218
 - as carotid artery aneurysm cause, 218
 - as innominate artery occlusive disease cause, 181
 - as mortality cause, 125
 - vascular. *See* Vascular injuries
 - Trendelenburg test, 14–15
 - Trental (oxypentifylline), 61–62
 - Triglycerides, 4, 58
- U**
- Ulceration
 - chronic venous, 109
 - epidemiology of, 105–106
 - management of, 113
 - physical therapy for, 110
 - foot/lower limb
 - differential diagnosis of, 14
 - ischemia-related, 91, 92, 93–94, 96–97
 - skin perfusion pressure evaluation of, 21–22
 - lymphedema-related, 116
 - Ulnar arteries
 - distal, cystic adventitial disease of, 89
 - traumatic injuries to, 130
 - Ultrasonography
 - of abdominal aortic aneurysms, 194–195, 198–199
 - Doppler
 - of arterial disease, 15–16, 19–20, 21
 - of arteriovenous fistulas, 123
 - fixed waved, 15–16
 - waveform analysis in, 21
 - duplex, 22–23, 150–151
 - of arteriovenous fistulas, 123
 - of axillary artery aneurysms, 218
 - carotid, 32, 164–165
 - of chronic venous insufficiency, 109
 - of cystic adventitial disease, 89
 - of popliteal arterial aneurysms, 211
 - post-carotid endarterectomy, 178
 - of the renal artery, 223
 - of subclavian arterial aneurysms, 217
 - of the subclavian artery, 186
 - of upper limb vascular disease, 32
 - of inflammatory abdominal aortic aneurysm, 207
 - United Kingdom Prospective Diabetes Study group, 167
 - University of Iowa, 67
 - Ureterolysis, 207
 - Urokinase, 101, 248
- V**
- Varices, pelvic, imaging of, 109
 - Varicose veins, 12
 - arteriovenous fistula-associated, 123
 - clinical evaluation of, 14–15
 - epidemiology of, 105–106
 - physical examination of, 108
 - radiofrequency or laser ablation treatment of, 67
 - recurrent, surgical treatment of, 112
 - secondary, 107
 - surgical treatment of, 111–113
 - Vascular access, 141–148
 - complications of, 144–147
 - desperate, 147–148
 - equipment for, 237–240
 - principles of, 141
 - standards for, 141–142
 - techniques in, 242–244
 - for thrombolytic therapy, 248
 - types of, 142–144
 - Vascular disease. *See also* Peripheral vascular disease
 - clinical evaluation of, 9–18
 - clinical examination in, 12–18
 - clinical history in, 9–12
 - patient's characteristics, 9
 - radiological studies in, 18
 - diabetes mellitus-related, 2
 - lipoprotein (a) as risk factor for, 4
 - nonatherosclerotic, 73–89
 - miscellaneous disorders, 86–89
 - vasculitis, 79–86
 - vasospastic disorders, 73–79
 - noninvasive examination of, 19–23
 - upper limb occlusive, 11–12
 - Vascular examination, noninvasive, 19–23
 - Vascular injuries, 125–132
 - abdominal, 128–130
 - combat-related, 125
 - diagnosis of, 126
 - of the extremities, 126, 130–131
 - iatrogenic, 126, 131
 - imaging of, 37
 - mechanism of injury in, 126
 - in the neck, 126, 127–128
 - thoracic, 128



- Vascular surgery. *See also* specific surgical procedures
complications of, 133–140
- Vasculitis, 79–86
cryoglobulinemic, 85–86
large-vessel, 80–82
medium-vessel, 82–83
small-vessel, 83–85
- Vasoconstriction, Raynaud's phenomenon-related, 73
- Vasodilation, erythromelalgia-related, 79
- Vasodilators, 241
- Vasospasm, Raynaud's phenomenon-related, 73
- Vasospastic disorders, 73–79
- Vein grafts, historical background of, 125
- Velocity analyses, 22
- Venoarteriolar reflex, lymphedema-related loss of, 116
- Venous disease
chronic, clinical evaluation of, 17
deep, symptoms of, 12
superficial, symptoms of, 12
symptoms of, 12
- Venous function, normal, 106–107
- Venous insufficiency
chronic, 17, 105–113
classification of, 105, 106
clinical assessment of, 107–109
epidemiology of, 105–106
nonsurgical management of, 109–111
pathophysiology of, 107
relationship with lymphedema, 118–119
surgical management of, 111–113
symptoms of, 108
- Venous systems, deep and superficial, 106–107
- Vertebral arteries
effect of subclavian stenosis on, 11
occlusive disease of, 188–190
traumatic injuries to, 128
- Vertebrobasilar symptoms, of stroke, 161, 163, 188–189
- Very-low density lipoprotein (VLDL), 2, 3, 4
- Veterans Administration, Surgical Quality Improvement Program (NSQIP), 149
- Vietnam Vascular Registry, 125
- Vietnam War, vascular surgery during, 125
- Visceral arteries, aneurysms of, 214–217
- Visceral ischemic syndromes, 231–236
acute mesenteric ischemia, 231–234
chronic visceral ischemia, 234–235
mesenteric venous thrombosis, 235–236
- Visuospatial neglect, 163
- von Willebrand disease, 43–44
- von Willebrand factor, 41
- W**
- Walking Impairment Questionnaire (WIQ), 152
- WALLSTENT study, 180
- Wegener, Friedrich, 83
- Wegener's granulomatosis, 83–84
- Weight gain, smoking cessation-related, 58
- Weight-loss programs, 57, 58
- World Wars I and II, vascular surgery development during, 125
- Wound healing, evaluation of, 21–22
- X**
- Xanthelasma, 12
- X-ray exposure, safety precautions for, 30–31
- X-rays
abdominal, of abdominal aortic aneurysms, 194
chest, of traumatic injuries, 37, 128
- Y**
- Yellow-nail syndrome, 117